Epilepsy Associates with Decreased HIF-1α/STAT5b Signaling in Glioblastoma.

GSEA HIF-1α STAT5b epilepsy glioblastoma hypoxia mesenchymal transformation tissue microarrays translational research

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
04 Jan 2019
Historique:
received: 09 11 2018
revised: 21 12 2018
accepted: 28 12 2018
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 10 1 2019
Statut: epublish

Résumé

Epilepsy at presentation is an independent favorable prognostic factor in glioblastoma (GBM). In this study, we analyze the oncologic signaling pathways that associate with epilepsy in human GBMs, and that can underlie this prognostic effect. Following ethical approval and patient consent, fresh frozen GBM tissue was obtained from 76 patient surgeries. Hospital records were screened for the presence of seizures at presentation of the disease. mRNA and miRNA expression-based and gene set enrichment analyses were performed on these tissues, to uncover candidate oncologic pathways that associate with epilepsy. We performed qPCR experiments and immunohistochemistry on tissue microarrays containing 286 GBMs to further explore the association of these candidate pathways and of markers of mesenchymal transformation (NF-κB, CEBP-β, STAT3, STAT5b, VEGFA, SRF) with epilepsy. Gene sets involved in hypoxia/HIF-1α, STAT5, CEBP-β and epithelial-mesenchymal transformation signaling were significantly downregulated in epileptogenic GBMs. On confirmatory protein expression analyses, epileptogenic tumors were characterized by a significant downregulation of phospho-STAT5b, a target of HIF-1α. Epilepsy status did not associate with molecular subclassification or miRNA expression patterns of the tumors. Epileptogenic GBMs correlate with decreased hypoxia/ HIF-1α/STAT5b signaling compared to glioblastomas that do not present with epilepsy.

Identifiants

pubmed: 30621209
pii: cancers11010041
doi: 10.3390/cancers11010041
pmc: PMC6356242
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fonds De La Recherche Scientifique - FNRS
ID : Televie 7.4.564.11.F
Organisme : Fonds De La Recherche Scientifique - FNRS
ID : FRSM 3.4.562.12
Organisme : Fonds De La Recherche Scientifique - FNRS
ID : 1.5.162.10
Organisme : Belgian Ministery of Health
ID : PNC-029 - 006
Organisme : Stichting Tegen Kanker
ID : FBC 2010.14
Organisme : T&P Bohnenn fund for Neuro-Oncological Research
ID : Unrestricted grant
Organisme : National Cancer Institute
ID : R01CA169368
Organisme : National Cancer Institute
ID : R01CA108633
Organisme : National Cancer Institute
ID : R01CA188228
Organisme : National Cancer Institute
ID : R01CA188500
Organisme : National Cancer Institute
ID : 1RC2CA148190
Organisme : Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
ID : Award
Organisme : National Cancer Institute
ID : P30 CA016058

Références

J Cell Biol. 2001 Nov 12;155(4):531-42
pubmed: 11706048
Mol Endocrinol. 2001 Dec;15(12):2157-71
pubmed: 11731617
FASEB J. 2005 Aug;19(10):1296-8
pubmed: 15919761
Breast. 2006 Apr;15(2):187-95
pubmed: 16084091
Exp Mol Med. 2005 Aug 31;37(4):353-64
pubmed: 16155412
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Clin Oncol. 2006 Jan 10;24(2):274-87
pubmed: 16365179
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
J Neurosurg. 2006 Jul;105(1):77-87
pubmed: 16874892
BMC Bioinformatics. 2006 Dec 01;7:526
pubmed: 17140431
Lancet Neurol. 2007 May;6(5):421-30
pubmed: 17434097
Biochem Biophys Res Commun. 2007 Jul 6;358(3):733-8
pubmed: 17509524
Cancer Lett. 2009 Jan 8;273(1):164-71
pubmed: 18793823
J Neurooncol. 2009 Jul;93(3):319-24
pubmed: 19183851
PLoS One. 2009 Jun 17;4(6):e5947
pubmed: 19536297
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
Nature. 2010 Jan 21;463(7279):318-25
pubmed: 20032975
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Neurosci Lett. 2011 Jan 7;487(2):228-33
pubmed: 20969921
PLoS One. 2012;7(2):e32448
pubmed: 22384254
Am J Pathol. 2012 May;180(5):2108-19
pubmed: 22440258
Int J Oncol. 2012 Jul;41(1):161-8
pubmed: 22552610
Int J Cancer. 2013 Feb 1;132(3):509-20
pubmed: 22729867
Neurology. 2012 Aug 28;79(9):883-9
pubmed: 22843268
PLoS One. 2012;7(10):e46425
pubmed: 23071568
Neuro Oncol. 2013 Jul;15(7):961-7
pubmed: 23680820
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cancer Cell. 2013 Oct 14;24(4):438-49
pubmed: 24135280
Epilepsy Res. 2014 Jul;108(5):843-52
pubmed: 24690158
Hepatology. 2015 Mar;61(3):979-89
pubmed: 25266280
Int J Cancer. 2015 May 1;136(9):2047-54
pubmed: 25302990
Neurosurg Focus. 2014 Dec;37(6):E17
pubmed: 25434386
J Immunol. 2015 Jan 1;194(1):21-7
pubmed: 25527793
Cancer Lett. 2015 Apr 1;359(1):107-16
pubmed: 25592037
Mol Neurobiol. 2016 Apr;53(3):1478-1493
pubmed: 25636686
Biomed Res Int. 2015;2015:324815
pubmed: 25699273
Sci Transl Med. 2015 May 27;7(289):289ra86
pubmed: 26019222
J Clin Neurosci. 2015 Oct;22(10):1655-60
pubmed: 26165472
Neuro Oncol. 2016 May;18(5):700-6
pubmed: 26420896
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
J Clin Oncol. 2016 Mar 1;34(7):731-9
pubmed: 26786929
Oncotarget. 2016 Jul 19;7(29):46088-46099
pubmed: 27323859
PLoS One. 2016 Aug 11;11(8):e0161202
pubmed: 27513743
Neuro Oncol. 2017 Mar 1;19(3):383-393
pubmed: 27591677
Oncotarget. 2016 Nov 29;7(48):79572-79583
pubmed: 27788487
Cell. 2017 Jan 12;168(1-2):37-57
pubmed: 28086098
BMC Cancer. 2017 Mar 1;17(1):163
pubmed: 28249598
Neurology. 2017 May 9;88(19):1805-1813
pubmed: 28404805
Mol Brain. 2017 Jul 17;10(1):30
pubmed: 28716058
Mol Med Rep. 2017 Dec;16(6):7890-7900
pubmed: 28983585
Epilepsy Behav. 2018 Jan;78:30-36
pubmed: 29172136
Seizure. 2018 Feb;55:76-82
pubmed: 29414139
Mol Cancer Res. 2018 Jul;16(7):1185-1195
pubmed: 29724813
Oncotarget. 2018 Apr 24;9(31):22095-22112
pubmed: 29774125
Nature. 1998 Jul 30;394(6692):485-90
pubmed: 9697772
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981

Auteurs

Sharon Berendsen (S)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. s.berendsen-2@umcutrecht.nl.

Wim G M Spliet (WGM)

Department of Pathology, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. W.G.M.Spliet@umcutrecht.nl.

Marjolein Geurts (M)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. M.Geurts-2@umcutrecht.nl.

Wim Van Hecke (W)

Department of Pathology, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. w.vanhecke@umcutrecht.nl.

Tatjana Seute (T)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. t.seute@umcutrecht.nl.

Tom J Snijders (TJ)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. T.J.Snijders@umcutrecht.nl.

Vincent Bours (V)

Department of Human Genetics, GIGA Research Center, University of Liège, Avenue de l Hôpital, 1, 4000 Liège, Belgium. vbours@uliege.be.

Erica H Bell (EH)

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital, The Ohio State University, West 10th Avenue, Columbus, OH 43210, USA. Erica.Bell@osumc.edu.

Arnab Chakravarti (A)

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital, The Ohio State University, West 10th Avenue, Columbus, OH 43210, USA. Arnab.Chakravarti@osumc.edu.

Pierre A Robe (PA)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. p.robe@umcutrecht.nl.
Department of Human Genetics, GIGA Research Center, University of Liège, Avenue de l Hôpital, 1, 4000 Liège, Belgium. p.robe@umcutrecht.nl.
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital, The Ohio State University, West 10th Avenue, Columbus, OH 43210, USA. p.robe@umcutrecht.nl.

Classifications MeSH